Breaching the gates

How Junction is using siRNAs to transiently breach the blood-brain barrier

Junction Therapeutics Ltd.’s siRNA-based technology creates transient openings in the blood-brain barrier by targeting tight junction proteins, allowing molecules to move in and out of the brain by diffusion. The approach enhances entry of therapies to treat cancers and CNS diseases, and promotes clearance from the brain of neurotoxic substances like β-amyloid.

Scientific co-founder Matthew Campbell told BioCentury the newco conjugates siRNA to a polyethylenimine

Read the full 640 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers